Aerska

About Aerska

Aerska is a biotechnology company focused on developing RNA medicines to treat, delay, and prevent diseases of the brain. Their mission is to deliver targeted RNA therapies systemically to the brain, silencing harmful genes to preserve minds, protect memories, and enable healthier, longer lives for patients with neurological disorders.

Products & Services

Next-Generation RNA Medicines:Innovative RNA interference (RNAi) therapies designed for unprecedented potency, durability, and precision in targeting disease origins intracellularly, specifically for central nervous system (CNS) disorders.

Systemic Brain Delivery Technology:Advanced brain shuttle technologies to deliver RNA medicines across the blood-brain barrier (BBB), building on partnerships and internal innovation for less invasive, targeted delivery to the brain.

Precision Medicine for CNS:Precision medicine approaches for neurological disorders, combining target biology, data-driven patient stratification, and biomarker-guided development to ensure patients receive the right treatment at the right time.

Specialties

RNA Interference (RNAi) Medicines Brain Shuttle Technologies Central Nervous System (CNS) Drug Development Precision Medicine for Neurological Disorders Systemic Brain Delivery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 39000000 MR: - FA: $39 million FAN: 39000000	D: 2026-02-09 FD: 2026-02-09	3 investors

Series A Latest

2026-02-09

$39.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jack O'Meara

Chief Executive Officer, Co-founder

S

Stuart Milstein

Platform & Innovation, Co-founder

D

Dave Hardwicke

Director, Head of Business Development, Co-founder

M

Michael Perkinton

VP, Head of Research

D

David Coughlan

VP, Head of Early Development

D

Duygu Yilmaz

Director, RNA Therapeutics & Translational Science

View 31 more team members with Pro

Unlock Full Team Directory

Recent News

Aerska Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised